Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.

"Competing interests EJ: Research grants and advisory roles (AbbVie, Adaptive Biotechnologies, Amgen, ASTX, Ascentage, Bristol Myers Squibb, Genentech, Jazz, Novartis, Pfizer, Takeda). JA: Honoraria, research funding, and speakers bureau (Incyte, Pfizer); honoraria and speakers bureau (Bristol Myers Squibb, Novartis). JC: Consultancy and research funding (Bristol Myers Squibb, Daiichi Sankyo, Jazz Pharmaceuticals, Astellas, Novartis, Pfizer, Takeda, BioPath Holdings); research funding (Sun Pharma, Telios, Arog, Merus, Immunogen); membership on an entity’s board of directors or advisory committees (BioPath Holdings); consultancy (Amphivena Therapeutics, BiolineRx). DR: Steering committee (Novartis); advisory board (Incyte, Pfizer, Novartis). MD: Consultancy, membership on an entity’s board of directors or advisory committees, part of a study management committee and research funding (Blueprint Medicines Corporation, Cogent); consultancy (Fusion Pharma, Medscape, DisperSol); consultancy, membership on an entity’s board of directors or advisory committees, and research funding (Takeda); consultancy and membership on an entity’s board of directors or advisory committees (Sangamo, CTO BioPharma); consultancy and research funding (Novartis); consultancy, honoraria, and research funding (Incyte); research funding (SPARC, DisperSol, Leukemia & Lymphoma Society). EA: Advisory board member and consultancy (Incyte, Novartis, Pfizer); honoraria (Bristol Myers Squibb). CC: Honoraria (Korea Otsuka Pharmaceutical); honoraria and research funding (Bristol Myers Squibb, Novartis); travel and research funding (Pfizer). DJD: Consulting and advisory role (Amgen, Autolos, Blueprint, Forty-Seven, Gilead, Incyte, Jazz, Novartis, Pfizer, Servier, and Takeda), research funding (all to institution: Novartis, AbbVie, GlycoMimetics, Blueprint Medicines). JD: Equity ownership (Magenta Therapeutics, WUGEN); board and advisory membership (RiverVest Venture Partners); research funding (Amphivena Therapeutics, NeoImmune Tech, Macrogenics, Incyte, BiolineRx, WUGEN); speaking fees (Incyte); patents/pending patents (CART with WashU and WUGEN, VLA-4 Inhibitors with WashU and Magenta). AH: Honoraria and research funding (Novartis, Incyte); research funding (Bristol Myers Squibb, Pfizer, MSD). JHL: Consultancy and research funding (Bristol Myers Squibb, ARIAD, Pfizer, Novartis). MM: Consultancy, honoraria, travel, accommodation, expenses, and research funding (Bristol Myers Squibb, Novartis, Takeda, Pfizer); research funding (Sun Pharma/SPARC). FN: Honoraria, speakers bureau, travel, accommodations, and expenses (Novartis, Incyte Biosciences, Pfizer); consulting and advisory role (Sun Pharma, Novartis, Analysis group); research fundings (Incyte Biosciences, Novartis); board entity (Novartis, Pfizer; Incyte Biosciences). JP-I: Consulting and advisory role (AbbVie, Janssen, AstraZeneca, Novartis, TG Therapeutics, Takeda); speakers bureau (AbbVie, Janssen, AstraZeneca, Takeda); research funding (MEI, Sunesis); patents, royalties, and other intellectual property (Sellas). GR: Research funding and speakers bureau (Pfizer); speakers bureau (Bristol Myers Squibb, Incyte, Novartis). PR: Consultancy and research funding (Incyte, Pfizer); consultancy (Bristol Myers Squibb, Novartis, Takeda). NS: Research funding (Bristol Myers Squibb). MT: Grant funding and research support (Takeda, Novartis). AV: Employment (Takeda). XR: Employment (Takeda). HK: Honoraria (AbbVie, Amgen, ARIAD, Bristol Myers Squibb, Immunogen, Orsenix, Pfizer, Agios, Takeda, Actinium Pharmaceuticals); research funding (all to institution: Pfizer, Amgen, Bristol Myers Squibb, Novartis, ARIAD, Astex Pharmaceuticals, AbbVie, Agios, Cyclacel, Immunogen, Jazz Pharmaceuticals)."

"The authors would like to thank the patients and their families, and the investigators and staff at all clinical sites, for their participation in the study. The study is sponsored by Takeda Development Center Americas, Inc. Medical writing support for the development of this manuscript, under the direction of the authors, was provided by Kalpana Vijayan, PhD, and Corey Burgin, PhD, of Peloton Advantage, LLC, an OPEN Health company, and funded by Takeda Development Center Americas, Inc., Lexington, MA, and complied with the Good Publication Practice (GPP) guidelines (DeTora LM, et al. Ann Intern Med. 2022;175:1298–1304)."